ReviewFrontiers in oncology2021
Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Repeat cytoreductive surgery with HIPEC for colorectal peritoneal metastases: a systematic review.World journal of surgical oncology · 2024Pooled it
- Intraperitoneal drug delivery systems releasing cytostatic agents to target gastro-intestinal peritoneal metastases in laboratory animals: a systematic review.Clinical & experimental metastasis · 2022Pooled it
- Experiences and Decisional Outcomes After Cytoreductive Surgery for Peritoneal Surface Malignancy: The DECISIVE Study.Annals of surgical oncology · 2026Article
- [BMJ open · 2026Observational
- Temporal Immune and Metabolic Shifts Drive the Anti-Tumor Efficacy of Resiquimod-Loaded Nanoparticles in Peritoneal Carcinomatosis.Advanced healthcare materials · 2026Article
- Differentiating malignancy from liver parenchyma in Ex-Vivo OCT images using anomaly detection.Scientific reports · 2026Article
- The Negative Impact of a Non-Therapeutic Laparotomy in Patients With Inoperable Colorectal Peritoneal Metastases.Journal of surgical oncology · 2026Article
- Evolving therapeutics in colorectal cancer peritoneal metastases.Cancer metastasis reviews · 2026Review
- Targeting the DNA damage response prevents regrowth of colorectal peritoneal metastasis-derived organoids following treatment with mitomycin C.British journal of cancer · 2026Article
- Review
- Preoperative Peritoneal MRI: Usefulness to Highlight Potential Hidden Lesions for Complete Cytoreductive Surgery in Patients with Colorectal Cancer with Surgical History.Annals of surgical oncology · 2026Article
- Emerging nano-immunotherapeutic strategies achieve metastatic colorectal cancer precision therapy.Journal of nanobiotechnology · 2026Review
- Clinical and molecular characterization ofJournal for immunotherapy of cancer · 2025Article
- Pan-cancer clinicopathological and genomic characteristics of peritoneal metastasis.NPJ precision oncology · 2025Article
- Peritoneal metastases from colorectal cancer managed by stereotactic body radiation therapy: presentation of a clinical case and review of literature.BJR case reports · 2025Article
- Review
- Overall survival post secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal cancer with peritoneal metastases.World journal of surgical oncology · 2025Article
- Primary and secondary metastatic dissemination: multiple routes to cancer-related death.Molecular cancer · 2025Review
- Influence of a nationwide colorectal cancer screening program on the incidence of synchronous colorectal peritoneal metastases.International journal of cancer · 2025Article
- Does side matter? Deciphering mechanisms that underpin side-dependent pathogenesis and therapy response in colorectal cancer.Molecular cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The presence of peritoneal metastases (PM) in patients with colorectal cancer (CRC) is associated with an extremely poor prognosis. The diagnosis of PM is challenging, resulting in an underestimation of their true incidence. While surgery can be curative in a small percentage of patients, effective treatment for non-operable PM is lacking, and clinical and pre-clinical studies are relatively sparse. Here we have defined the major clinical challenges in the areas of risk assessment, detection, and treatment. Recent developments in the field include the application of organoid technology, which has generated highly relevant pre-clinical PM models, the application of diffusion-weighted MRI, which has greatly improved PM detection, and the design of small clinical proof-of-concept studies, which allows the efficient testing of new treatment strategies. Together, these developments set the stage for starting to address the clinical challenges. To help structure these efforts, a translational research framework is presented, in which clinical trial design is based on the insight gained from direct tissue analyses and pre-clinical (organoid) models derived from CRC patients with PM. This feed-forward approach, in which a thorough understanding of the disease drives innovation in its clinical management, has the potential to improve outcome in the years to come.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.